Comparison of azasetron and ondansetron for preventing postoperative nausea and vomiting in patients undergoing gynecological laparoscopic surgery
- PMID: 20046519
- PMCID: PMC2799968
- DOI: 10.3349/ymj.2010.51.1.88
Comparison of azasetron and ondansetron for preventing postoperative nausea and vomiting in patients undergoing gynecological laparoscopic surgery
Abstract
Purpose: We compared the prophylactic effects of intravenously administered azasetron (10 mg) and ondansetron (8 mg) on postoperative nausea and vomiting (PONV) in patients undergoing gynecological laparoscopic surgery under general anesthesia.
Materials and methods: We studied 98 ASA physical status I or II 20-65 years old, female patients, in this prospective, randomized, double blind study. Patients were randomly divided into two groups and received ondansetron 8 mg (group O) or azasetron 10 mg (group A) 5 min before the end of surgery. The incidence of PONV, Visual Analogue Scale (VAS) for pain, need for rescue antiemetic and analgesics, and adverse effects were checked at 1, 6, 12, 24, and 48 h postoperatively.
Results: The overall incidence of PONV was 65% in group O and 49% in group A. The incidence of PONV was significantly higher in group O than in group A at 12-24 h postoperatively (nausea; 24% vs. 45%, p = 0.035, vomiting; 2% vs. 18%, p = 0.008), but there were no significant differences at 0-1, 1-6, 6-12 or 24-48 h.
Conclusion: In conclusion, azasetron (10 mg) produced same incidence of PONV as ondansetron (8 mg) in patients undergoing general anesthesia for gynecological laparoscopic surgery. Azasetron was more effective, in the intermediate post-operative period, between 12 and 24 h.
Keywords: Azasetron; gynecologic surgical procedures; ondansetron; postoperative nausea and vomiting; prophylaxis.
Conflict of interest statement
The authors have no financial conflicts of interest.
Similar articles
-
The effect of preoperative ondansetron on the incidence of postoperative nausea and vomiting in patients undergoing outpatient dentoalveolar surgery and general anesthesia.J Oral Maxillofac Surg. 1999 Oct;57(10):1195-200. doi: 10.1016/s0278-2391(99)90485-8. J Oral Maxillofac Surg. 1999. PMID: 10513865 Clinical Trial.
-
Alizapride and ondansetron for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic gynaecological surgery: A double-blind, randomised, placebo-controlled noninferiority study.Eur J Anaesthesiol. 2016 Feb;33(2):96-103. doi: 10.1097/EJA.0000000000000288. Eur J Anaesthesiol. 2016. PMID: 26086285 Clinical Trial.
-
A prospective, randomized, double-blind, and multicenter trial of prophylactic effects of ramosetronon postoperative nausea and vomiting (PONV) after craniotomy: comparison with ondansetron.BMC Anesthesiol. 2014 Aug 4;14:63. doi: 10.1186/1471-2253-14-63. eCollection 2014. BMC Anesthesiol. 2014. PMID: 25104916 Free PMC article. Clinical Trial.
-
Efficacy of palonosetron in postoperative nausea and vomiting (PONV)-a meta-analysis.J Clin Anesth. 2016 Nov;34:459-82. doi: 10.1016/j.jclinane.2016.05.018. Epub 2016 Jun 28. J Clin Anesth. 2016. PMID: 27687434 Review.
-
Postoperative Nausea and Vomiting in Female Patients Undergoing Breast and Gynecological Surgery: A Narrative Review of Risk Factors and Prophylaxis.Front Med (Lausanne). 2022 Jul 1;9:909982. doi: 10.3389/fmed.2022.909982. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35847822 Free PMC article. Review.
Cited by
-
Compatible stability of methylprednisolone sodium succinate and tropisetron in 0.9% sodium chloride injection.Eur J Hosp Pharm. 2020 Mar;27(e1):e58-e62. doi: 10.1136/ejhpharm-2018-001693. Epub 2018 Dec 1. Eur J Hosp Pharm. 2020. PMID: 32296507 Free PMC article.
-
Penehyclidine enhances the efficacy of tropisetron in prevention of PONV following gynecological laparoscopic surgery.J Anesth. 2012 Dec;26(6):864-9. doi: 10.1007/s00540-012-1443-1. Epub 2012 Aug 10. J Anesth. 2012. PMID: 22878869 Clinical Trial.
-
Comparative safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis.BMC Med. 2015 Jun 18;13:142. doi: 10.1186/s12916-015-0379-3. BMC Med. 2015. PMID: 26084332 Free PMC article.
-
Stability of azasetron-dexamethasone mixture for chemotherapy-induced nausea and vomiting administration.Oncotarget. 2017 Oct 31;8(63):106249-106257. doi: 10.18632/oncotarget.22174. eCollection 2017 Dec 5. Oncotarget. 2017. PMID: 29290945 Free PMC article.
-
A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy.Cancer Res Treat. 2014 Jan;46(1):19-26. doi: 10.4143/crt.2014.46.1.19. Epub 2014 Jan 15. Cancer Res Treat. 2014. PMID: 24520219 Free PMC article.
References
-
- Gan TJ. Postoperative nausea and vomiting--can it be eliminated? JAMA. 2002;287:1233–1236. - PubMed
-
- Ismail S. Practice of use of antiemetic in patients for laparoscopic gynaecological surgery and its impact on the early (1st two hrs) postoperative period. J Pak Med Assoc. 2008;58:203–205. - PubMed
-
- Gan TJ, Meyer T, Apfel CC, Chung F, Davis PJ, Eubanks S, et al. Consensus guidelines for managing postoperative nausea and vomiting. Anesth Analg. 2003;97:62–71. - PubMed
-
- White PF, Watcha MF. Postoperative nausea and vomiting: prophylaxis versus treatment. Anesth Analg. 1999;89:1337–1339. - PubMed
-
- Tsukagoshi S. [Pharmacokinetics of azasetron (Serotone), a selective 5-HT3 receptor antagonist.] Gan To Kagaku Ryoho. 1999;26:1001–1008. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources